Cochrane · systematic review · CD011709
Chlorpromazine versus piperacetazine for schizophrenia
Eslami Shahrbabaki, M, Dehnavieh, R, Vali, L, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
2
Included studies
NR
No studies 2 · 28.6%Ungraded 0 · 0%Very low 5 · 71.4%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Chlorpromazine versus piperacetazine for schizophrenia
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: clinically important change ‐ as defined by each of the studies Chlorpromazine vs piperacetazine | RR 0.9 [0.8, 1.02] | 2 studies · 208 participants | Very low Downgraded: imprecision, publication bias |
Mental state: overall mean change score (BPRS total, high = poor)* Chlorpromazine vs piperacetazine | no estimate extracted | 1 study · 182 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Mental state: specific ‐ clinically important change in negative symptoms Chlorpromazine vs piperacetazine | no estimate extracted | NR | No studies |
Adverse effects/events: incidence of adverse effects ‐ as defined by each of the studies Chlorpromazine vs piperacetazine | RR 1 [0.75, 1.33] | 3 studies · 74 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Adverse effects/events: clinically important movement disorder (Parkinsonism) Chlorpromazine vs piperacetazine | RR 0.95 [0.61, 1.49] | 3 studies · 106 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Leaving the study early ‐ for any reason Chlorpromazine vs piperacetazine | RR 0.5 [0.1, 2.56] | 4 studies · 256 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Economic costs Chlorpromazine vs piperacetazine | no estimate extracted | NR | No studies |